Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 16Dexamethasone 14Melphalan 12Bortezomib 11Filgrastim 6Peripheral Blood Stem Cell Transplantation 5Lenalidomide 5Thalidomide 4Prednisone 4sargramostim 3fludarabine phosphate 3daratumumab 3Radiotherapy 3Mycophenolic Acid 3Interferon-alpha 3Doxorubicin 3Busulfan 3Antilymphocyte Serum 3pomalidomide 2isatuximab 2fludarabine 2Vincristine 2Methylprednisolone 2Idarubicin 2Cyclosporine 2Carmustine 2plerixafor 1pegfilgrastim 1orantinib 1epoetin beta 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms, Plasma Cell × alethine × Clear all
NCT00006466 2013-12-18

Beta Alethine in Treating Patients With Myeloma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡